Although previous studies indicate that expression of the GPR35 gene is reduced in humans and mice with osteoporosis, stimulation of monocytes with GPR35 agonists significantly increased GPR35 expression in pre-osteoclasts and mature osteoclasts, indicating that the receptor is a viable target. Here, GPR35 is linked to osteoporosis.